Cargando…
Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
AIM OF THE STUDY: Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection. MATERIAL...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728861/ https://www.ncbi.nlm.nih.gov/pubmed/31501787 http://dx.doi.org/10.5114/ceh.2019.84782 |
_version_ | 1783449494287810560 |
---|---|
author | Piekarska, Anna Mamzer-Dachnowska, Aleksandra Kasprzak, Jarosław D. Peruga, Jan Z. Kaszuba, Andrzej Berkan-Kawińska, Aleksandra |
author_facet | Piekarska, Anna Mamzer-Dachnowska, Aleksandra Kasprzak, Jarosław D. Peruga, Jan Z. Kaszuba, Andrzej Berkan-Kawińska, Aleksandra |
author_sort | Piekarska, Anna |
collection | PubMed |
description | AIM OF THE STUDY: Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection. MATERIAL AND METHODS: Testing for the presence of anti-HCV antibodies was performed in a group of patients admitted to the Cardiology Department with symptomatic ischemic heart disease (IHD) and in patients hospitalised in the Dermatology Department. RESULTS: A total of 1171 patients underwent anti-HCV testing: 672 patients in the Cardiology Department (K group) and 499 patients in the Dermatology Department (D group). Twenty-eight (2.4%) positive anti-HCV results were detected. The prevalence of positive anti-HCV antibodies in groups K and D was 2.23% and 2.61%, respectively (p > 0.05). Presence of HCV RNA was confirmed in 15 cases (1.28%) – 7 patients in group K and 8 patients in group D (1.04% and 1.6%, respectively; p > 0.05). CONCLUSIONS: Our findings suggest that this patient cohort has increased risk of HCV infection, which may influence screening strategies. |
format | Online Article Text |
id | pubmed-6728861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-67288612019-09-09 Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study Piekarska, Anna Mamzer-Dachnowska, Aleksandra Kasprzak, Jarosław D. Peruga, Jan Z. Kaszuba, Andrzej Berkan-Kawińska, Aleksandra Clin Exp Hepatol Original Paper AIM OF THE STUDY: Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection. MATERIAL AND METHODS: Testing for the presence of anti-HCV antibodies was performed in a group of patients admitted to the Cardiology Department with symptomatic ischemic heart disease (IHD) and in patients hospitalised in the Dermatology Department. RESULTS: A total of 1171 patients underwent anti-HCV testing: 672 patients in the Cardiology Department (K group) and 499 patients in the Dermatology Department (D group). Twenty-eight (2.4%) positive anti-HCV results were detected. The prevalence of positive anti-HCV antibodies in groups K and D was 2.23% and 2.61%, respectively (p > 0.05). Presence of HCV RNA was confirmed in 15 cases (1.28%) – 7 patients in group K and 8 patients in group D (1.04% and 1.6%, respectively; p > 0.05). CONCLUSIONS: Our findings suggest that this patient cohort has increased risk of HCV infection, which may influence screening strategies. Termedia Publishing House 2019-04-30 2019-05 /pmc/articles/PMC6728861/ /pubmed/31501787 http://dx.doi.org/10.5114/ceh.2019.84782 Text en Copyright: © 2019 Clinical and Experimental Hepatology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Piekarska, Anna Mamzer-Dachnowska, Aleksandra Kasprzak, Jarosław D. Peruga, Jan Z. Kaszuba, Andrzej Berkan-Kawińska, Aleksandra Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study |
title | Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study |
title_full | Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study |
title_fullStr | Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study |
title_full_unstemmed | Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study |
title_short | Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study |
title_sort | prevalence of hepatitis c virus infection in patients hospitalised for ischemic heart disease versus controls – pro-cardio-c study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728861/ https://www.ncbi.nlm.nih.gov/pubmed/31501787 http://dx.doi.org/10.5114/ceh.2019.84782 |
work_keys_str_mv | AT piekarskaanna prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy AT mamzerdachnowskaaleksandra prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy AT kasprzakjarosławd prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy AT perugajanz prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy AT kaszubaandrzej prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy AT berkankawinskaaleksandra prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy |